Influenza and respiratory syncytial virus in the elderly

Expert Review of Vaccines

Volumn 7, Issue 2, 2008, Pages 249-258

  Elliot, Alex J ^a   Fleming, Douglas M ^a  

^a ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

Author keywords

Acute bronchitis; Elderly; Hospital admissions; Influenza; Influenza vaccine; Influenza like illness; Mortality; Respiratory syncytial virus

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; PALIVIZUMAB; RIMANTADINE; ZANAMIVIR;

AVIAN INFLUENZA; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FLU LIKE SYNDROME; GERIATRIC PATIENT; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MORTALITY; PANDEMIC; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREND STUDY; VIRAL RESPIRATORY TRACT INFECTION; VIRUS TRANSMISSION;

AGED; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 40549092991     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.2.249     Document Type: Review

References (111)

1. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 17(Suppl. 1), S3-S10 (1999).
2. Smith DJ, Lapedes AS, de Jong JC et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305(5682), 371-376 (2004).
3. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol. Rev. 56(1), 152-179 (1992).
4. Taubenberger JK, Reid AH, Lourens RM et al. Characterization of the 1918 influenza virus polymerase genes. Nature 437(7060), 889-893 (2005).
5. Chotpitayasunondh T, Lochindarat S, Srisan P et al. Cases of influenza A (H5N1) - Thailand, 2004. MMWR Morb. Mortal. Wkly Rep. 53, 100-103 (2004).
6. Tran TH, Nguyen TL, Nguyen TD et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med. 350(12), 1179-1188 (2004).
7. Webster RG, Govorkova EA. H5N1 influenza - continuing evolution and spread. N. Engl. J. Med. 355(21), 2174-2177 (2006).
8. Webby RJ, Webster RG. Are we ready for pandemic influenza? Science 302(5650), 1519-1522 (2003).
9. Fouchier RA, Schneeberger PM, Rozendaal FW et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl Acad. Sci. USA 101(5), 1356-1361 (2004).
10. Peiris M, Yuen KY, Leung CW et al. Human infection with influenza H9N2. Lancet 354(9182), 916-917 (1999).
11. Nicholson KG. Human influenza. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds). Blackwell Sciences, Oxford, UK 219-264 (1998).
12. Fleming DM, Elliot AJ, Cross KW. Morbidity profiles of patients consulting during influenza and respiratory syncytial virus active periods. Epidemiol. Infect. 135(7), 1099-1108 (2007).
13. de Jong MD, Bach VC, Phan TQ et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N. Engl. J. Med. 352(7), 686-691 (2005).
14. Brady MT, Sears SD, Pacini DL et al. Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic. Antimicrob. Agents Chemother. 34(9), 1633-1636 (1990).
15. Dolin R, Reichman RC, Madore HP et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N. Engl. J. Med. 307(10), 580-584 (1982).
16. Hall CB, Dolin R, Gala CL et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 80(2), 275-282 (1987).
17. Hayden FG, Monto AS. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob. Agents Chemother. 29(2), 339-341 (1986).
18. Hayden FG, Sperber SJ, Belshe RB et al. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob. Agents Chemother. 35(9), 1741-1747 (1991).
19. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 4(11), 3021-3024 (1985).
20. Monto AS. The role of antivirals in the control of influenza. Vaccine 21(16), 1796-1800 (2003).
21. Hayden FG, Belshe RB, Clover RD et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N. Engl. J. Med. 321(25), 1696-1702 (1989).
22. Mast EE, Harmon MW, Gravenstein S et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am. J. Epidemiol. 134(9), 988-997 (1991).
23. Ziegler T, Hemphill ML, Ziegler ML et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J. Infect. Dis. 180(4), 935-939 (1999).
24. Barr IG, Hurt AC, Deed N et al. The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006. Antiviral Res. 75(2), 173-176 (2007).
25. Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366(9492), 1175-1181 (2005).
26. Saito R, Li D, Suzuki Y et al. High prevalence of amantadine-resistance influenza A (H3N2) in six prefectures, Japan, in the 2005-2006 season. J. Med. Virol. 79(10), 1569-1576 (2007).
27. Cheung CL, Rayner JM, Smith GJ et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193(12), 1626-1629 (2006).
28. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 70(3), 121-131 (2006).
29. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther. 12(3), 363-370 (2007).
30. Aoki FY, Macleod MD, Paggiaro P et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother. 51(1), 123-129 (2003).
31. Monto AS, Fleming DM, Henry D et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J. Infect. Dis. 180(2), 254-261 (1999).
32. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J. Antimicrob. Chemother. 44(Suppl. B), 23-29 (1999).
33. Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355(9218), 1845-1850 (2000).
34. Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283(8), 1016-1024 (2000).
35. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg. Infect. Dis. 11(2), 201-209 (2005).
36. The Writing Committee of the WHO Consultation on Human Influenza. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353, 1374-1385 (2005).
37. Govorkova EA, Ilyushina NA, Boltz DA et al. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother. 51(4), 1414-1424 (2007).
38. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 45(10), 2723-2732 (2001).
39. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 48(2), 101-115 (2000).
40. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55(Suppl. 1), i5-i21 (2005).
41. Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20(2), 127-133 (2001).
42. de Jong MD, Tran TT, Truong HK et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353(25), 2667-2672 (2005).
43. Le QM, Kiso M, Someya K et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437(7062), 1108 (2005).
44. Lackenby A, Hungnes O, Dudman SG et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 13(5) (2008) (Epub ahead of print).
45. Department of Health. CMO's Update: Major Changes to the Policy on Influenza Immunisation. UK Department of Health, (2000).
46. Donaldson L, Beasley C, Ridge K. The Influenza Immunisation Programme 2007/2008. UK Department of Health, London, UK (2007).
47. Joseph C, Goddard N, Gelb D. Influenza vaccine uptake and distribution in England and Wales using data from the General Practice Research Database, 1989/90-2003/04. J. Public Health 27(4), 371-377 (2005).
48. Rivetti D, Jefferson T, Thomas R et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev. 3, CD004876 (2006).
49. Govaert TM, Thijs CT, Masurel N et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 272(21), 1661-1665 (1994).
50. + T cell responses to influenza vaccine. J. Immunol. 173(1), 673-681 (2004).
51. McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 23(Suppl. 1), S10-S25 (2005).
52. Jefferson T. Influenza vaccination: policy versus evidence. Br. Med. J. 333(7574), 912-915 (2006).
53. Jefferson T, Rivetti D, Rivetti A et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366(9492), 1165-1174 (2005). • Comprehensive meta-analysis of the effectiveness of influenza vaccines in the elderly that questions the overall effectiveness of the impact of these vaccines in certain elderly populations.
54. Jordan RE, Hawker JI, Ayres JG et al. A case-control study of elderly patients with acute respiratory illness: effect of influenza vaccination on admission to hospital in winter 2003-2004. Vaccine 25(46), 7909-7913 (2007).
55. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect.Dis. 7(10), 658-666 (2007). •• Assesses the benefits of influenza vaccination in relation to mortality in the elderly. The authors highlight inconsistencies between previous studies and identify areas where further research is required.
56. Mufson MA, Levine HD, Wasil RE, Mocega-Gonzalez HE, Krause HE. Epidemiology of respiratory syncytial virus infection among infants and children in Chicago. Am. J. Epidemiol. 98(2), 88-95 (1973).
57. Nicholson KG, McNally T, Silverman M et al. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine 24(1), 102-108 (2006).
58. Parrott RH, Kim HW, Arrobio JO et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am. J. Epidemiol. 98(4), 289-300 (1973).
59. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr. Infect. Dis. J. 22(9), 823-827 (2003).
60. The Impact Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102(3), 531-537 (1998).
61. Zambon MC, Stockton JD, Clewley JP, Fleming DM. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 358(9291), 1410-1416 (2001). • Community-based observational study that estimates the contribution of influenza and respiratory syncytial virus (RSV) to clinical cases of influenza-like illness. This study demonstrates that RSV can cause respiratory illness in patients of all ages.
62. Ross AM, Kai J, Salter R, Ross J, Fleming DM. Presentation with influenza-like illness in general practice: implications for use of neuraminidase inhibitors. Commun. Dis. Public Health 3(4), 256-260 (2000).
63. Walsh EE, Peterson DR, Falsey AR. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible? J. Infect. Dis. 195(7), 1046-1051 (2007). • Important study that compares the clinical characteristics of RSV and influenza A infections in the elderly and, thereby, provides a better understanding of the clinical syndromes associated with each virus.
64. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J. Infect. Dis. 189(2), 233-238 (2004).
65. Fleming DM, Elliot AJ, Nguyen-van Tam JS, Watson JM, Wise R. A Winter's Tale: Coming to Terms with Winter Respiratory Illnesses. Health Protection Agency, London, UK (2005).
66. Goddard NL, Kyncl J, Watson JM. Appropriateness of thresholds currently used to describe influenza activity in England. Commun. Dis. Public Health 6(3), 238-245 (2003).
67. Salisbury DM. Influenza Season 2005/06 - Use of Oseltamivir. Department of Health, London, UK (2006).
68. Fleming DM, Elliot AJ. Changing disease incidence: the consulting room perspective. Br. J. Gen. Pract. 56(532), 820-824 (2006).
69. Standing Medical Advisory Committee Subcommittee on Antibiotic Resistance. In: The Path of Least Resistance. Hart M, Livermoore DM, Weinberg JR (Eds). Department of Health, London, 1-152 (1998).
70. Lowen AC, Mubareka S, Steel J, Palese P. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog. 3(10), 1470-1476 (2007).
71. Elliot AJ, Fleming DM. Surveillance of influenza-like illness in England and Wales during 1966-2006. Euro Surveill. 11(10), 249-250 (2006).
72. Fleming DM. The contribution of influenza to combined acute respiratory infections, hospital admissions, and deaths in winter. Commun. Dis. Public Health 3(1), 32-38 (2000).
73. Elliot AJ, Cross KW, Fleming DM. Acute respiratory infections and winter pressures on hospital admissions in England and Wales 1990-2005. J. Public Health 30(1), 91-98 (2008).
74. Simonsen L, Fukuda K, Schonberger LB, Cox NJ. The impact of influenza epidemics on hospitalizations. J. Infect. Dis. 181(3), 831-837 (2000).
75. Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA 292(11), 1333-1340 (2004). •• USA-based study examining hospital discharge and laboratory data to estimate influenza-associated hospitalisations. The authors found significant numbers of influenza-associated hospitalisations in the elderly, which have increased over the last 20 years due to the increasing aging population.
76. Mangtani P, Hajat S, Kovats S, Wilkinson P, Armstrong B. The association of respiratory syncytial virus infection and influenza with emergency admissions for respiratory disease in London: an analysis of routine surveillance data. Clin. Infect. Dis.42(5), 640-646 (2006).
77. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352(17), 1749-1759 (2005). •• Provides excellent data on the clinical burden of RSV infections in the elderly and high-risk adults and its effect on hospitalizations. The study concludes that the disease burden associated with RSV is equal to that of nonpandemic influenza.
78. Falsey AR, Cunningham CK, Barker WH et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. 172(2), 389-394 (1995).
79. Mullooly JP, Bridges CB, Thompson WW et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine 25(5), 846-855 (2007).
80. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med. 331(12), 778-784 (1994).
81. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20(13-14), 1831-1836 (2002).
82. Monto AS, Comanor L, Shay DK, Thompson WW. Epidemiology of pandemic influenza: use of surveillance and modeling for pandemic preparedness. J. Infect. Dis. 194(Suppl. 2), S92-S97 (2006).
83. Department of Health. UK Health Department's Influenza Pandemic Contingency Plan. Department of Health, London, UK (2005).
84. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2), 179-186 (2003).
85. Fleming DM, Cross KW, Pannell RS. Influenza and its relationship to circulatory disorders. Epidemiol. Infect. 133(2), 255-262 (2005).
86. Elliot AJ, Cross KW, Smith GE, Fleming DM. Do children drive the spread of influenza-like illness in the community? Presented at: Options for the Control of Influenza VI. Toronto, Canada, 17-23 June 2007.
87. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N. Engl. J. Med. 357(14), 1373-1381 (2007).
88. Wang CS, Wang ST, Lai CT, Lin LJ, Chou P. Impact of influenza vaccination on major cause-specific mortality. Vaccine 25(7), 1196-1203 (2007).
89. Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur. Respir. J. 23(3), 363-368 (2004).
90. Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 357(9261), 1008-1011 (2001).
91. Ortqvist A, Granath F, Askling J, Hedlund J. Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area. Eur. Respir. J. 30(3), 414-422 (2007).
92. Rizzo C, Viboud C, Montomoli E, Simonsen L, Miller MA. Influenza-related mortality in the Italian elderly: no decline associated with increasing vaccination coverage. Vaccine 24(42-43), 6468-6475 (2006).
93. Mangtani P, Cumberland P, Hodgson CR et al. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J. Infect. Dis. 190(1), 1-10 (2004).
94. Simonsen L, Reichert TA, Viboud C et al. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch. Intern. Med. 165(3), 265-272 (2005).
95. Paget WJ, Meerhoff TJ, Meijer A. Epidemiological and virological assessment of influenza activity in Europe during the 2003-2004 season. Euro Surveill. 10(4), 107-111 (2005).
96. Openshaw PJ, Culley FJ, Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20(Suppl. 1), S27-S31 (2001).
97. Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89(4), 422-434 (1969).
98. Wright PF, Karron RA, Belshe RB et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25(42), 7372-7378 (2007).
99. Baldo V, Menegon T, Bonello C, Floreani A, Trivello R. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 19(25-26), 3472-3475 (2001).
100. De Donato S, Granoff D, Minutello M et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17(23-24), 3094-3101 (1999).
101. Minutello M, Senatore F, Cecchinelli G et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17(2), 99-104 (1999).
102. de Bruijn I, Meyer I, Gerez L et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 26(1), 119-127 (2007).
103. Ruf BR, Colberg K, Frick M, Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 32(4), 191-198 (2004).
104. Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 21(11-12), 1268-1274 (2003).
105. Fiore AE, Shay DK, Haber P et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recommended Report 56(RR-6), 1-54 (2007).
106. Treanor JJ, Betts RF. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Vaccine 16(18), 1756-1760 (1998).
107. Rudenko LG, Arden NH, Grigorieva E et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 19(2-3), 308-318 (2000).
108. Weekly Returns Service Annual Report 2006. Birmingham Research Unit of the Royal College of General Practitioners www.rcgp.org.uk/ continuing_the_gp_journey/bru/annual_reports
109. Confirmed human cases of avian influenza A(H5N1). WHO (2007) www.who.int/csr/disease/avian_influenza/country/
110. Hospital Episode Statistics: primary diagnosis 3 character - 2005/06. Hospital Episode Statistics Online (2007) www.hesonline.org.uk/Ease/servlet/ ContentServer?siteID=1937&categoryID=203
111. National Statistics Online. Mortality statistics - DH historical series (2007) www.statistics.gov.uk/statbase/explorer.asp?CTG=3&SL=4250&D= 4729&DCT=32&DT=32#4729